[HTML] sciencedirect.com

[HTML][HTML] Mesenchymal stem cells and management of COVID-19 pneumonia

SM Metcalfe - Medicine in drug discovery, 2020 - Elsevier
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …
被引用次数：179 相关文章

[引用][C] Mesenchymal stem cells and management of COVID-19 pneumonia

SM Metcalfe - Medicine in Drug Discovery, 2020 - cir.nii.ac.jp
[HTML] nih.gov

[HTML][HTML] Mesenchymal stem cells and management of COVID-19 pneumonia

SM Metcalfe - Medicine in Drug Discovery, 2020 - ncbi.nlm.nih.gov
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …

Mesenchymal stem cells and management of COVID-19 pneumonia

SM Metcalfe - Medicine in drug discovery, 2020 - pubmed.ncbi.nlm.nih.gov
Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with
rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 …

Mesenchymal stem cells and management of COVID-19 pneumonia.

SM Metcalfe - Medicine in Drug Discovery, 2020 - europepmc.org
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …

Mesenchymal stem cells and management of COVID-19 pneumonia.

SM Metcalfe - 2020 - repository.cam.ac.uk
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …

Mesenchymal stem cells and management of COVID-19 pneumonia.

SM Metcalfe - Medicine in Drug Discovery, 2020 - europepmc.org
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …